Drug Trial Radar · NCT02607956
Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults
Last checked: Nov 19, 2026Latest source record: Mar 7, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
657
Actual
Start
Nov 11, 2015
Primary completion
May 12, 2017
Study completion Jul 5, 2021
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Nov 18, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This primary objective of this study is to evaluate the efficacy of a fixed dose combination (FDC) containing bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus dolutegravir (DTG) + a FDC containing emtricitabine/tenofovir alafenamide (F/TAF) in HIV-1 infected, antiretroviral treatment-naive adults.
Conditions
- HIV-1 Infection
Interventions
DTGDrug
50 mg tablets administered orally, once daily
F/TAFDrug
200/25 mg tablets administered orally, once daily
B/F/TAFDrug
50/200/25 milligrams (mg) FDC tablets administered orally, once daily
DTG PlaceboDrug
Tablets administered orally, once daily
F/TAF PlaceboDrug
Tablets administered orally, once daily
B/F/TAF PlaceboDrug
Tablets administered orally, once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot AlgorithmTime frame: Week 48
Locations
125 sites in 11 countries. Site status is shown where the registry gives one.
Site not named
Phoenix, Arizona
Site not named
Phoenix, Arizona
Site not named
Beverly Hills, California
Site not named
Los Angeles, California
Site not named
Los Angeles, California
Site not named
Los Angeles, California
Site not named
Los Angeles, California
Site not named
Sacramento, California
Site not named
Sacramento, California
Optimus Medical - ClinEdge - PPDS
San Francisco, California
Kaiser Permanente
San Leandro, California
Site not named
Denver, Colorado
Site not named
Washington D.C., District of Columbia
Site not named
Washington D.C., District of Columbia
Site not named
Washington D.C., District of Columbia
Site not named
DeLand, Florida
Site not named
Fort Lauderdale, Florida
Site not named
Ft. Pierce, Florida
Site not named
Miami, Florida
Site not named
Miami, Florida
Site not named
Miami Beach, Florida
Site not named
Oakland Park, Florida
Site not named
Orlando, Florida
Site not named
Pensacola, Florida
Site not named
Tampa, Florida
Site not named
West Palm Beach, Florida
Site not named
Atlanta, Georgia
Site not named
Atlanta, Georgia
Site not named
Decatur, Georgia
Site not named
Macon, Georgia
Site not named
Savannah, Georgia
Site not named
Chicago, Illinois
Site not named
Chicago, Illinois
Site not named
Indianapolis, Indiana
Sinai Hospital of Baltimore
Baltimore, Maryland
Site not named
Boston, Massachusetts
Site not named
Boston, Massachusetts
Site not named
Springfield, Massachusetts
Site not named
Berkley, Michigan
Site not named
Detroit, Michigan
Showing 40 of 125 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.